文献速递冠心病

吗啡与非ST段抬高型急性冠脉综合征患者接受冠脉造影后的心血管结局

Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

本研究基于EARLY ACS试验,分析5,438例接受氯吡格雷治疗的NSTEACS患者中吗啡与缺血事件的关联,并以3,462例未用氯吡格雷者作阴性对照。结果显示,使用氯吡格雷时吗啡与96小时四终点事件风险升高相关(校正OR 1.40),30天死亡或心梗有升高趋势;未用氯吡格雷者无此关联。

要点

  • NSTEACS用氯吡格雷时,吗啡与96小时缺血复合终点风险升高相关。
  • 未用氯吡格雷者中吗啡与缺血事件无显著关联,支持交互作用。
  • 30天死亡或心梗风险有升高趋势,事件主要集中在前48小时。

核心结论

  • 在NSTEACS患者中,与氯吡格雷预处理同时使用吗啡与更高的缺血事件率相关。

研究设计与样本

  • 基于EARLY ACS试验的回顾性分析,纳入5,438例接受氯吡格雷治疗的NSTEACS患者,并以3,462例未用氯吡格雷者作阴性对照。

主要发现

  • 氯吡格雷治疗者中,吗啡与96小时四终点事件(死亡、心梗、再发缺血或血栓性补救)风险升高相关(校正OR 1.40,95%CI 1.04–1.87,p=0.026)。
  • 氯吡格雷治疗者中,30天死亡或心梗有升高趋势(校正OR 1.29,95%CI 0.98–1.70,p=0.072),主要由前48小时事件驱动(校正HR 1.54,95%CI 1.07–2.23,p=0.021)。
  • 未用氯吡格雷者中,吗啡与96小时四终点事件(校正OR 1.05,95%CI 0.74–1.49,p=0.79;交互p=0.36)及30天死亡或心梗(校正OR 1.07,95%CI 0.77–1.48,p=0.70;交互p=0.46)均无显著关联。

临床怎么用

  • 对接受氯吡格雷预处理的NSTEACS患者,应权衡吗啡镇痛与潜在缺血风险。

局限性

  • 本研究为基于EARLY ACS试验的回顾性分析,吗啡使用非随机分配,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mechanistic studies have shown that morphine blunts the antiplatelet effects of oral adenosine diphosphate receptor blockers. However, the clinical relevance of this interaction is controversial. OBJECTIVES: This study sought to explore the association between morphine and ischemic events in 5,438 patients treated with concomitant clopidogrel presenting with non-ST-segment elevation acute coronary syndromes (NSTEACS) in the EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome) trial. Patients not treated with clopidogrel (n = 3,462) were used as negative controls. METHODS: Endpoints were the composite of death, myocardial infarction (MI), recurrent ischemia, or thrombotic bailout at 96 h (4-way endpoint) and the composite of death or MI at 30 days. RESULTS: In patients treated with clopidogrel, morphine use was associated with higher rates of the 4-way endpoint at 96 h (adjusted odds ratio [OR]: 1.40; 95% confidence interval [CI]: 1.04 to 1.87; p = 0.026). There was a trend for higher rates of death or MI at 30 days (adjusted OR: 1.29; 95% CI: 0.98 to 1.70; p = 0.072), driven by events in the first 48 h (adjusted hazard ratio: 1.54; 95% CI: 1.07 to 2.23; p = 0.021). In patients not treated with clopidogrel, morphine was not associated with either the 4-way endpoint at 96 h (adjusted OR: 1.05; 95% CI: 0.74 to 1.49; p = 0.79; pinteraction = 0.36 ) or death or MI at 30 days (adjusted OR: 1.07; 95% CI: 0.77 to 1.48; p = 0.70; pinteraction = 0.46). CONCLUSIONS: When used concomitantly with clopidogrel pre-treatment, morphine was associated with higher rates of ischemic events in patients with NSTEACS. (EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome; NCT00089895).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Furtado RHM, Nicolau JC, Guo J, et al. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. J Am Coll Cardiol. 2020. PMID: 31976867. doi:10.1016/j.jacc.2019.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。